{"schema_version":"1.0","type":"article","title":"RevMed Says No to Being Bought: Biotech's Independent Era","url":"https://drugnews.com.tw/articles/2026-07-03-revmed-biotech-en.html","markdown_url":"https://drugnews.com.tw/articles/2026-07-03-revmed-biotech-en.md","lang":"en","date":"2026-07-03","publish_at":"2026-07-03T10:30:00+08:00","updated_at":"2026-07-03","category":"商業分析系列","topic":"商業分析系列","tags":["Revolution Medicines","RevMed","daraxonrasib","RAS oncology","biotech business analysis","Taiwan biotech","BD licensing","biotech valuation","clinical data","capital markets"],"summary":"Revolution Medicines is choosing not to make a sale its priority. The decision reflects a broader shift: top-tier biotech companies with breakthrough assets may once again have a credible path to grow into independent biopharma companies.","key_points":[],"facts":[],"sections":["01 | Why RevMed Is Not Rushing to Sell","02 | Daraxonrasib Is RevMed's Independence Ticket","03 | RevMed Is Not Trying to Sell One Drug. It Is Trying to Build a RAS Franchise","04 | Why Biotech Independence Is More Possible Now","05 | What Makes RevMed Different: It Has a Reusable First Card","06 | Independence Is Not a Romantic Story. RevMed Still Faces Three Hard Battles","07 | Taiwan View: Not Every Company Should Stay Independent, but Every Company Needs a Next-Step Answer","Conclusion | RevMed's Refusal Reflects a Change in Biotech's Role","References"],"references":[{"title":"[0] Company websites and public disclosures.","source":"","date":"","url":""},{"title":"[1] Financial Times report on Revolution Medicines, Merck discussions, and management's stance on a sale:","source":"","date":"","url":"https://www.ft.com/content/3b1e5908-1cf4-4cc8-ade2-f0636a90739c"},{"title":"[2] Investors.com coverage of Revolution Medicines and daraxonrasib pancreatic-cancer data:","source":"","date":"","url":"https://www.investors.com/news/technology/revolution-medicines-stock-pancreatic-cancer-treatment/"},{"title":"[3] Royalty Pharma company disclosures and public information:","source":"","date":"","url":"https://www.royaltypharma.com/"},{"title":"[4] U.S. FDA information on Besremi approval for polycythemia vera:","source":"","date":"","url":"https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-treatment-rare-blood-disease"},{"title":"[5] Foresee Pharmaceuticals public information on CAMCEVI:","source":"","date":"","url":"https://www.foreseepharma.com/"},{"title":"[6] Formosa Pharmaceuticals public information on APP13007:","source":"","date":"","url":"https://www.formosapharma.com/"}],"images":[{"alt":"Why RevMed is not rushing to sell","url":"https://drugnews.com.tw/assets/articles/revmed-biotech-en/figure-01.png"},{"alt":"Daraxonrasib is RevMed's independence ticket","url":"https://drugnews.com.tw/assets/articles/revmed-biotech-en/figure-02.png"},{"alt":"From single drug to RAS franchise","url":"https://drugnews.com.tw/assets/articles/revmed-biotech-en/figure-03.png"},{"alt":"Taiwan biotech paths to the next stage","url":"https://drugnews.com.tw/assets/articles/revmed-biotech-en/figure-04.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/revmed-biotech-en/cover.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-07-03）。RevMed Says No to Being Bought: Biotech's Independent Era。https://drugnews.com.tw/articles/2026-07-03-revmed-biotech-en.html","disclaimer":"This article is intended for industry research and knowledge sharing only. It does not constitute investment, medical, fundraising, or individual stock advice.","translations":{"zh-Hant":"2026-07-03-revmed-biotech.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}